Immunovant, Inc. Common Stock (IMVT)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Immunovant, Inc. Common Stock (IMVT) is listed on Nasdaq, where it has traded since June 21, 2019.
- Listed On
- Nasdaq
- Listed Since
- June 21, 2019
- Employees
- 315
- Market Cap
- $6.1B
About Immunovant, Inc. Common Stock
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 216 institutions reported holding IMVT, with 110.1 million shares worth $4.2 billion in aggregate. The largest reported holder was FMR, with 16.2 million shares worth $623.7 million. Of the 5 largest holders listed below, 3 added shares and 2 reduced their positions during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 16,186,469 | $624M | Reduced 4.49% |
| Deep Track Capital | 9,341,151 | $360M | Reduced 18.96% |
| Vanguard | 8,240,910 | $318M | Added 2.98% |
| BlackRock | 7,180,897 | $277M | Added 9.22% |
| Farallon Capital Management | 5,805,000 | $224M | Added 275.49% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is IMVT?
Immunovant, Inc. Common Stock (IMVT) is listed on Nasdaq, where it has traded since June 21, 2019.
Who are the largest institutional holders of IMVT?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IMVT were FMR, Deep Track Capital and Vanguard.
How many institutions own IMVT?
216 institutions reported a position in IMVT for the quarter ended June 30, 2026, worth $4.2 billion in total.
Did institutions buy or sell IMVT last quarter?
Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter. Every reported holder and its change is on the SentiSense ownership page for IMVT.
Every reported institutional holder, plus insider and congressional trades in IMVT, on SentiSense.